What it sells
AI-assisted oculomics.
Business model breakdown
Buyer: who owns the budget?
UnverifiedNHS hospital eye departments and primary-care eyecare providers (likely trust leadership/clinical leads).
Trigger: what makes them buy now?
High-volume, high-risk eye disease (e.g. nAMD treatment monitoring) where clinicians need evidence-based decision support to prevent avoidable sight loss.
Workflow: what inputs become what output?
Models ingest macula-centred OCT cubes and give clinical decision support for retinal disease and treatment monitoring; oculomics uses retinal imaging to detect systemic disease (cardiovascular, neurodegeneration, dementia) early.
Distribution: how it reaches customers
UnverifiedBacked and co-launched by Moorfields Eye Hospital, UCL Institute of Ophthalmology and Topcon Healthcare (imaging device maker), implying hospital and device-partner channels.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-09-24 | Seed | — | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.